Literature DB >> 29794146

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Farhad Ravandi1, Ellen K Ritchie2, Hamid Sayar3, Jeffrey E Lancet4, Michael D Craig5, Norbert Vey6, Stephen A Strickland7, Gary J Schiller8, Elias Jabbour9, Arnaud Pigneux10, Heinz-August Horst11, Christian Récher12, Virginia M Klimek13, Jorge E Cortes9, Angelo-Michele Carella14, Miklos Egyed15, Utz Krug16, Judith A Fox17, Adam R Craig17, Renee Ward17, Jennifer A Smith17, Gary Acton17, Hagop M Kantarjian9, Robert K Stuart18.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29794146      PMCID： PMC6278965          DOI： 10.3324/haematol.2018.191361

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

Authors:  D Grimwade; H Walker; G Harrison; F Oliver; S Chatters; C J Harrison; K Wheatley; A K Burnett; A H Goldstone
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

2.  Age and acute myeloid leukemia.

Authors:  Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

3.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.

Authors:  C P Leith; K J Kopecky; J Godwin; T McConnell; M L Slovak; I M Chen; D R Head; F R Appelbaum; C L Willman
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

4.  Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.

Authors:  Rachael E Hawtin; David E Stockett; Jo Ann W Byl; Robert S McDowell; Tan Nguyen; Michelle R Arkin; Andrew Conroy; Wenjin Yang; Neil Osheroff; Judith A Fox
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

5.  Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.

Authors:  Francis Giles; Norbert Vey; Daniel DeAngelo; Karen Seiter; Wendy Stock; Robert Stuart; Darinka Boskovic; Arnaud Pigneux; Martin Tallman; Joseph Brandwein; Jonathan Kell; Tadeusz Robak; Peter Staib; Xavier Thomas; Ann Cahill; Maher Albitar; Susan O'Brien
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

6.  Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.

Authors:  Arati V Rao; Peter J M Valk; Klaus H Metzeler; Chaitanya R Acharya; Sascha A Tuchman; Marvaretta M Stevenson; David A Rizzieri; Ruud Delwel; Christian Buske; Stefan K Bohlander; Anil Potti; Bob Löwenberg
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

7.  Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Authors:  Farhad Ravandi; Ellen K Ritchie; Hamid Sayar; Jeffrey E Lancet; Michael D Craig; Norbert Vey; Stephen A Strickland; Gary J Schiller; Elias Jabbour; Harry P Erba; Arnaud Pigneux; Heinz-August Horst; Christian Recher; Virginia M Klimek; Jorge Cortes; Gail J Roboz; Olatoyosi Odenike; Xavier Thomas; Violaine Havelange; Johan Maertens; Hans-Günter Derigs; Michael Heuser; Lloyd Damon; Bayard L Powell; Gianluca Gaidano; Angelo-Michele Carella; Andrew Wei; Donna Hogge; Adam R Craig; Judith A Fox; Renee Ward; Jennifer A Smith; Gary Acton; Cyrus Mehta; Robert K Stuart; Hagop M Kantarjian
Journal:  Lancet Oncol       Date:  2015-07-30       Impact factor: 41.316

8.  Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

Authors:  Klaus H Metzeler; Tobias Herold; Maja Rothenberg-Thurley; Susanne Amler; Maria C Sauerland; Dennis Görlich; Stephanie Schneider; Nikola P Konstandin; Annika Dufour; Kathrin Bräundl; Bianka Ksienzyk; Evelyn Zellmeier; Luise Hartmann; Philipp A Greif; Michael Fiegl; Marion Subklewe; Stefan K Bohlander; Utz Krug; Andreas Faldum; Wolfgang E Berdel; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann; Jan Braess; Karsten Spiekermann
Journal:  Blood       Date:  2016-06-10       Impact factor: 22.113

9.  Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

Authors:  Stefan Faderl; Meir Wetzler; David Rizzieri; Gary Schiller; Madan Jagasia; Robert Stuart; Siddhartha Ganguly; David Avigan; Michael Craig; Robert Collins; Michael Maris; Tibor Kovacsovics; Stuart Goldberg; Karen Seiter; Parameswaran Hari; Jochen Greiner; Norbert Vey; Christian Recher; Farhad Ravandi; Eunice S Wang; Michael Vasconcelles; Dirk Huebner; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

Review 10.  Relapsed acute myeloid leukemia: why is there no standard of care?

Authors:  Farhad Ravandi
Journal:  Best Pract Res Clin Haematol       Date:  2013-10-16       Impact factor: 3.020
View more
  3 in total

1.  A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents.

Authors:  Tim R Blower; Afif Bandak; Amy S Y Lee; Caroline A Austin; John L Nitiss; James M Berger
Journal:  Nucleic Acids Res       Date:  2019-09-05       Impact factor: 16.971

Review 2.  Relapsed or primary refractory AML: moving past MEC and FLAG-ida.

Authors:  Kristin Koenig; Alice Mims
Journal:  Curr Opin Hematol       Date:  2020-03       Impact factor: 3.218

3.  Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents.

Authors:  Antonino Nicolò Fallica; Carla Barbaraci; Emanuele Amata; Lorella Pasquinucci; Rita Turnaturi; Maria Dichiara; Sebastiano Intagliata; Marzia Bruna Gariboldi; Emanuela Marras; Viviana Teresa Orlandi; Claudia Ferroni; Cecilia Martini; Antonio Rescifina; Davide Gentile; Greta Varchi; Agostino Marrazzo
Journal:  J Med Chem       Date:  2021-07-28       Impact factor: 8.039
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.